MedTrace Logo

Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy

NCT00951132 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-02

No results posted yet for this study

Summary

The purpose of this study is to investigate whether rosuvastatin decreases measures of inflammation in depressive patients.

Conditions

Interventions

DRUG

rosuvastatin

10mg tablets, once daily in three months

DRUG

Placebo

tablet, once daily, three months

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • University Hospital, Akershus

    lead OTHER

Principal Investigators

  • Torbjorn Omland, PhD · University Hospital, Akershus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-12-31
Completion
2013-12-31

Countries

  • Norway

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00951132 on ClinicalTrials.gov